Bausch + Lomb Reports 9% Revenue Growth to $1.394 Billion in Q2 2026

Bausch + Lomb Corporation reported a notable increase in financial performance for the second quarter of 2026, with total revenues reaching $1.394 billion, a 9% increase from $1.278 billion in the same period last year. The growth was primarily driven by higher product sales, which amounted to $1.389 billion, up from $1.272 billion in the prior year. The company also reported an operating income of $83 million, a significant turnaround from an operating loss of $11 million in the second quarter of 2025. However, Bausch + Lomb recorded a net loss of $14 million, an improvement from a net loss of $62 million in the previous year.

In the first half of 2026, Bausch + Lomb's revenues totaled $2.638 billion, compared to $2.415 billion in the same period of 2025, marking a 9% increase. The company attributed this growth to increased net pricing, higher sales volumes across its segments, and favorable foreign currency impacts. The Vision Care segment generated $1.495 billion in revenue, while the Pharmaceuticals and Surgical segments contributed $659 million and $484 million, respectively. The company also noted a decrease in its cost of goods sold as a percentage of product sales, which fell to 38.4% from 41.7% year-over-year.

Strategically, Bausch + Lomb has been active in expanding its product offerings and capabilities. The company has focused on its research and development efforts, with approximately 900 employees dedicated to advancing its pipeline, which includes new contact lenses and treatments for various eye conditions. The company also completed several acquisitions, including a manufacturing facility in Mexico, aimed at enhancing its production capacity and operational efficiency. Additionally, Bausch + Lomb is in the process of separating from its parent company, Bausch Health Companies Inc., a move that is expected to provide greater operational independence and strategic focus.

Operationally, Bausch + Lomb reported a slight increase in its employee headcount, reflecting its ongoing investments in product development and market expansion. The company continues to monitor global market conditions, including geopolitical tensions and trade policies, which could impact its operations and financial performance. As of June 30, 2026, Bausch + Lomb had total assets of $13.859 billion and total liabilities of $7.415 billion, with a cash and cash equivalents balance of $367 million.

Looking ahead, Bausch + Lomb remains optimistic about its growth prospects, driven by its robust product pipeline and strategic initiatives. The company anticipates continued revenue growth and operational improvements, although it acknowledges potential risks related to market conditions, regulatory changes, and the ongoing separation process from Bausch Health. The management's outlook emphasizes a commitment to enhancing shareholder value while navigating the complexities of the eye health market.